A new study suggests that people with atopic dermatitis (AD) treated with dupilumab face roughly double the risk of developing vitiligo, a condition causing loss of skin pigmentation. However, the actual number of people affected remains small, with only about 2 in 1,000 dupilumab patients developing vitiligo compared to 1 in 1,000 on other systemic treatments . The findings highlight the importance of informed conversations between patients and dermatologists before starting this popular medication.

What Did the Research Actually Show?

Researchers conducted a large propensity score-matched cohort study using the TriNetX US Collaborative Network, comparing adults with atopic dermatitis treated with dupilumab to those receiving other systemic therapies, including corticosteroids, methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine . After matching, the study included 27,723 patients in the dupilumab group and 27,868 in the control group, tracking new-onset vitiligo within 3 years of treatment initiation.

The results showed vitiligo incidence of 0.206% in the dupilumab group compared with 0.104% in controls, corresponding to a relative risk of 1.976, meaning dupilumab users were roughly twice as likely to develop vitiligo . Despite this relative increase, the absolute risk difference was only 0.102%, underscoring that vitiligo remains a rare adverse event in this setting.

Why Should Patients Care About This Finding?

Dupilumab has transformed treatment for moderate-to-severe atopic dermatitis, offering relief from intense itching, inflammation, and skin barrier dysfunction that can severely impact quality of life. However, vitiligo carries its own psychosocial burden. The condition causes visible patches of depigmented skin, often triggering emotional distress and social anxiety in affected individuals. Understanding this potential trade-off allows patients to make fully informed decisions about their treatment path.

The research also noted something intriguing: while some patients developed new vitiligo after starting dupilumab, others experienced resolution of pre-existing vitiligo during treatment . This suggests the relationship between dupilumab and vitiligo is complex and may vary significantly from person to person.

How Should Patients Approach This Information?

• Have a Detailed Conversation: Before starting dupilumab, discuss your personal and family history of vitiligo with your dermatologist. If you have relatives with vitiligo or any history of pigmentary changes, this becomes especially important to mention.
• Monitor for Pigmentary Changes: During dupilumab treatment, watch for any new patches of lighter skin, particularly on your face, hands, or areas exposed to sun. Early detection allows your dermatologist to intervene quickly if vitiligo does develop.
• Weigh Benefits Against Risks: For many people with severe atopic dermatitis, the dramatic improvement in skin inflammation and itching outweighs the small risk of vitiligo. Your dermatologist can help you assess whether dupilumab is the right choice for your specific situation.
• Explore Alternative Options: If you have significant concerns about vitiligo risk, discuss other systemic treatments with your dermatologist. The study compared dupilumab to several alternatives that may be appropriate for your condition.

"AD patients treated with dupilumab were more likely to develop vitiligo after treatment initiation. The absolute risk difference was small, indicating this as a rare adverse event. Given the psychosocial burden of vitiligo, clinicians should still be aware of this potential outcome when counseling patients and monitoring during therapy," the study authors concluded.

Study Authors, American Academy of Dermatology Annual Meeting

The research emphasizes that while dupilumab's overall benefit-risk profile remains favorable for atopic dermatitis treatment, awareness and monitoring are essential. Dermatologists should proactively discuss this potential side effect during initial consultations, and patients should feel empowered to ask questions about their individual risk factors .

If you're considering dupilumab or currently taking it, schedule a conversation with your dermatologist about your personal risk profile and what warning signs to watch for. Early detection and intervention can minimize the impact of any pigmentary changes that might develop.